公开(公告)号：WO2021113328A1

公开(公告)日：2021-06-10

申请号：PCT/US2020/062840

申请日：2020-12-02

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  DOLGOTER, Aleksandr ,  HUNDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian

IPC: A61K39/00

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof.

公开(公告)号：WO2022094391A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057543

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha Balakrishnan ,  MOHLER, Kendall M. ,  SHAWLER, Daniel Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing breast cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the breast cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022094386A1

公开(公告)日：2022-05-05

申请号：PCT/US2021/057536

申请日：2021-11-01

Applicant: NEUVOGEN, INC. [US]/[US]

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNTDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/575 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.

公开(公告)号：WO2022094388A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057539

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/55538 ,  A61K2039/70 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86 ,  A61K2039/884 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001151 ,  A61K39/001152 ,  A61K39/001153 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001168 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001195 ,  A61K39/39

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing colorectal cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to driver mutations. Also provided herein are methods of making and preparing the colorectal cancer vaccine compositions and methods of use thereof.

公开(公告)号：WO2022094386A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057536

申请日：2021-11-01

Applicant: NEUVOGEN, INC.

Inventor： FERRARO, Bernadette ,  ARNDT, Justin, James ,  BINDER, Todd, Merrill ,  HUNTDT, Matthias ,  LEWIS, Amritha, Balakrishnan ,  MOHLER, Kendall, M. ,  SHAWLER, Daniel, Lee ,  YAN, Jian ,  BAGARAZZI, Mark

IPC: A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (I) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (II) express or increase expression of one or more immunostimulatory factors by the cells, and/or (ill) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens, and/or (iv) express one or more tumor fitness advantage mutations, including but not limited to acquired tyrosine kinase inhibitor (TKI) resistance mutations, EGFR activating mutations, and/or (v) express modified ALK intracellular domain(s), and/or express one or more driver mutations. Also provided herein are methods of making and preparing the vaccine compositions and methods of use thereof.